Better Access to Unemployment Insurance Treatment Can Positively Affect Women’s Health and Reduce Payer Costs
BOSTON, June 21, 2022 /PRNewswire/ — Renovia Inc. (Renovia), a women-led company developing digital therapies for female pelvic floor disorders, today announced that a recently published, peer-reviewed study has shown that women with stress urinary incontinence (SUI) and mixed urinary incontinence (MUI) consume significantly more medical resources and incur higher costs for payers, compared to women without SUI/MUI. The study was published in Neurourology and urodynamics, the official journal of the Society of Urodynamics and Female Pelvic Medicine & Urogenital Reconstruction.
The study, “Healthcare Resource Use and Cost Burden of Urinary Incontinence to United States Payers,” assessed the use and costs of healthcare resources for patients diagnosed with stress or mixed urinary incontinence (SUI / MUI) compared to a cohort of 1:1 matched patients without SUI/MUI. Over a two-year period, the group of women with SUI/MUI had significantly more hospital, outpatient, primary care, and specialist visits compared to the group of women without incontinence. In fact, payers incurred 61% higher total costs for women with SUI/MUI. Although the reasons for the increased use of resources and costs are multifactorial and therefore difficult to isolate, the study authors concluded that “increased attention to insurance assessment and treatment -unemployment by payers and health systems may present an opportunity to reduce overall medical costs and improve health in women with UI.”
Urinary incontinence (UI) is a very common health problem affecting more than 60% of adult women. UI is characterized by involuntary leakage of urine and is classified into several subtypes, the most common being stress, urgency and mixed, which account for approximately 95% of UI diagnoses. Stress user interface (SUI) involves leaking with sneezing, coughing, or physical exertion. Urgency UI (UUI) refers to the involuntary loss of urine associated with a sudden, urge to urinate that is difficult to delay. Mixed user interface (MUI) is the symptom complaint of both SUI and UUI.
“This is an important study that confirms what pelvic floor reconstruction surgeons, like myself, have intuitively known for years. ” noted Dr. Tanaz Ferzandidirector of the division of urogynecology and pelvic reconstructive surgery and associate professor of obstetrics and gynecology at the Keck School of Medicine in University of Southern California. “I’ve seen a trend across the entire healthcare ecosystem to look at user interface as a lifestyle issue that’s largely treated without a prescription with adult diapers and pads, sometimes pessaries This study confirms that user interface is a problem at the payer and health system level.”
Adverse effects on quality of life, economics, and health have been well documented in women with untreated UI. It is a progressive condition, more likely to worsen over time than to stabilize or resolve when left untreated. Several studies show that pelvic floor muscle training (PFMT), commonly known as Kegel exercises, can offer an effective first-line treatment for urinary incontinence. However, most women cannot effectively strengthen and train their pelvic floor by performing Kegel exercises themselves.
“Urinary incontinence places an enormous burden on patients, including approximately 70% of the cost of conservative care and UI symptom management, and now this study adds to our understanding of the significant costs incurred by payers” , said Jessica McKinney, PT, DScPT, MS, Vice President of Medical Affairs and Clinical Advocacy at Renovia and author of this study. “It is imperative to provide women with access to effective, evidence-based treatments at every stage of the care journey. Numerous studies have demonstrated the efficacy and safety of take Pelvic Health System, a simple first-line treatment for UI used by women at home, making it a valuable way to improve UI symptoms before they progress and prompting women to seek additional care.
The take Pelvic Health System is an FDA-cleared prescription digital therapy (PDT) that combines a small vaginal motion sensor with a smartphone app that guides a woman through treatment, providing women with an easy, noninvasive, and painless way to medication to effectively strengthen their pelvic floor muscles to improve UI symptoms. take requires just five minutes of training a day, which women can do at home, on their own schedule. In April 2022, Obstetrics and Gynecology (The Green Journal), published a randomized controlled superiority study showing that take was statistically and clinically superior to Kegels alone in improving symptoms of stress and mixed stress-dominant urinary incontinence.
About take® Pelvic health system
The take Pelvic Health System offers women a new, non-invasive, drug-free way to train and strengthen their pelvic floor muscles – at home in just five minutes a day – to treat urinary incontinence (UI). Combining a small FDA-approved vaginal motion sensor connected to a smartphone app, take provides accurate real-time visualization of pelvic movement, enables progress tracking, and allows for the active participation of clinicians, all of which support women’s success. Recognizing that level one evidence shows that pelvic floor muscle training is most effective when performed under the supervision of a qualified healthcare professional, take is available by prescription only, empowering clinicians to treat UI at scale and with a deep commitment to patient success. take is the first femtech product included in the Digital Therapeutics Alliance product library and has multiple clinical trials and published data from globally recognized medical centers supporting its effectiveness in treating UI. take received the 2021 Medical Device Network Research Excellence Award.
BostonRenovia Inc. is a women-led company dedicated to improving the lives of women with pelvic floor disorders. Renovia’s flagship product, the take® Pelvic health system, offers a new, effective first-line treatment for urinary incontinence (UI), an underreported condition affecting 78 million women in the United States alone. Renovia’s technology enables non-invasive, drug-free treatment through accurate visualization of real-time movement during pelvic floor muscle training, while monitoring usage and progress. For more information on Renovia or take please visit www.renoviainc.com and www.levatherapy.com and follow us on TwitterFacebook, LinkedIn and Instagram.
Important instructions and other information for the take Pelvic health system
The take Pelvic Health System is intended for strengthening pelvic floor muscles and rehabilitating and training weak pelvic floor muscles for the treatment of mild to moderate stress, mixed and urge urinary incontinence (including overactive bladder) in women. Treatment with the take The system is prescription and is not for everyone. Please speak to your prescribing physician to see if take is good for you. Your prescriber should discuss all potential benefits and risks with you. Do not use take during pregnancy or if you think you may be pregnant, unless approved by your doctor. For a full summary of the risks and instructions for takesystem, consult its instructions for use available on www.renoviainc.com and www.levatherapy.com.
Renovia Inc. and take® are trademarks or registered trademarks of Renovia Inc. in United States and other countries. All rights reserved.
SOURCE Renovia Inc.